fbpx
Connect with us

News

Brainomix teams up with Pixyl to expand MS offering

Published

on

Pixyl

UK medical software developer Brainomix has announced a new partnership with Grenoble-based neuro-imaging company Pixyl.

The collaboration will see Brainomix distribute Pixyl’s Neuro.MS  Software as a Service (SaaS) solution, which is used in the diagnosis and treatment of patients with multiple sclerosis.

Pixyl’s deep-learning technology enables radiologists and clinicians to quickly access clinically relevant information for neurological disorders like multiple sclerosis (MS).

The CE-marked class IIa Neuro.MS automatically analyses brain MRI images to identify, quantify and track abnormalities in under five minutes.

The solution provides access to quantified measures of lesion volume and brain atrophy, as well as white matter hyperintensities, which are quantified and classified.

Brainomix will be distributing the SaaS solution exclusively in the UK and Ireland, the Nordics and key markets across Eastern Europe.

Brainomix CEO and co-founder, Dr Michalis Papadakis, said:

“We are excited to embark on this partnership with Pixyl – a company with whom we share a common vision focused on developing innovative, AI-powered solutions that can enhance diagnostic and treatment decisions.

“We recognised that there was an opportunity to form these types of third-party technology partnerships, as a way of offering our customers a broader set of AI-enabled solutions.

“We have achieved great success with our e-Stroke platform, and now look to apply that expertise to Pixyl’s Neuro.MS SaaS solution, helping to spur wider clinical adoption of this best-in-class technology.”

The Neuro.MS solution will be offered to Brainomix’s existing customer base alongside Brainomix’s e-Stroke platform, which has been widely adopted in multiple healthcare systems worldwide, including the NHS.

Pixyl co-founder and CEO, Senan Doyle, said:

“Leveraging Brainomix’s large installed base and dedicated sales force in some of Europe’s leading markets represents a strategic step in our vision to broaden the adoption of AI-powered, clinically relevant solutions to drive better patient outcomes in the neurology imaging space.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories